Vaccine efficacy based on 2 doses: Bharat Biotech after Vij tests positive

Covaxin is an indigenously developed Covid-19 vaccine undergoing a trial on over 26,000 people across 25 sites in India to evaluate the efficacy of the vaccine candidate

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Representational image of the Covid-19 vaccine developed by Bharat Biotech.
Sohini Das Mumbai
2 min read Last Updated : Dec 05 2020 | 6:22 PM IST
After Haryana minister Anil Vij, who is a participant in the phase 3 clinical trial of Bharat Biotech's investigational Covid19 vaccine candidate, tested positive for the Sars-CoV-2 virus, the Hyderabad based vaccine maker clarified that Covaxin has been designed to be efficacious based on a two-dose schedule, given 28-days apart.

The company also clarified that the vaccine efficacy will be determined 14-days post the second dose. Further, Bharat Biotech International (BBIL) said that the phase 3 trials are double blinded and randomised where 50 per cent of the subjects will receive the vaccine, and 50 per cent would receive the placebo. BBIL also confirmed that the minister had not yet received two doses of the vaccine.


On Saturday, Vij tweeted, "I have been tested Corona positive. I am admitted in Civil Hospital Ambala Cantt. All those who have come in close contact to me are advised to get themselves tested for corona." According to reports, he participated in the trial on November 20.

At the moment, there is no way to determine whether the minister got the vaccine or the placebo shot.

Dr Shahid Jameel, senior virologist and director at Ashoka University explained that there were a couple of possibilities - one is that the minister is in a placebo group and since the trial is ongoing, the code cannot be broken to ascertain this. "Secondly, only one shot does not give sufficient immunity. He is not fully immunised as per protocol from phase 1 and phase 2 testing. Also, even after a full course of vaccination, some people can still get infected but the disease is mild," Dr Jameel said.

Covaxin is an indigenously developed Covid19 vaccine undergoing a trial on over 26,000 people across 25 sites in India to evaluate the efficacy of the vaccine candidate.

--- Company says 50% subjects receive placebo
--- Trial is on 26,000 subjects
--- Trial is double blinded and randomised
--- In an ongoing trial, one cannot break the code to know if minister received vaccine or placebo
--- Company says 14-days after two shots given 28-days apart, efficacy is to be determined
--- Experts even after full immunisation, people can get the disease, albeit a mider form

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusBharat BiotechCoronavirus VaccineCoronavirus Tests

Next Story